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Abstract
Background: There is a growing support for the stance that patients and research participants should have better
and easier access to their raw (uninterpreted) genomic sequence data in both clinical and research contexts.
Main body: We review legal frameworks and literature on the benefits, risks, and practical barriers of providing
individuals access to their data. We also survey genomic sequencing initiatives that provide or plan to provide
individual access. Many patients and research participants expect to be able to access their health and genomic
data. Individuals have a legal right to access their genomic data in some countries and contexts. Moreover,
increasing numbers of participatory research projects, direct-to-consumer genetic testing companies, and now
major national sequencing initiatives grant individuals access to their genomic sequence data upon request.
Conclusion: Drawing on current practice and regulatory analysis, we outline legal, ethical, and practical guidance for
genomic sequencing initiatives seeking to offer interested patients and participants access to their raw genomic data.
Keywords: Ethics, Law, Genomic data, Individual access, Whole genome sequencing, Direct-to-consumer, Privacy,
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Background
The quantity of genomic data generated about individual
patients, research participants, and consumers is rapidly
increasing. The Global Alliance for Genomics and
Health (GA4GH), an international public-private consor-
tium, develops technical standards and frames policy to
facilitate the sharing of health and genomic data be-
tween health care, research, and individuals. Analyzing
and sharing these data leads to novel health insights and
opportunities [1], but it raises ethical questions about
the flow of data back to individuals. Debate has centered
on what types of individual findings should be reported
from testing or research [2] and has tended to focus on
the clinical validity and actionability of results, and
whether or not individuals want to receive them [3, 4].
A distinct but equally important question is whether or
not patients or research participants should be able to
access to their “raw” (uninterpreted) genomic sequence
data [5, 6].
A task team of the GA4GH on individual access was
established to explore how genomic data generated in
both clinical and health research contexts can be more
readily shared with individual patients and participants.
Research participants primarily want data that is clinic-
ally relevant to them or their families [7, 8]. They also
attach intrinsic value to genomic data and expect to be
able to access data that “belongs to them.” Of 4140 indi-
viduals participating in an ongoing international GA4GH
survey, 61% would want to be able to access their raw
sequence data (with most having the intention to use the
data as the basis of further exploration) [9]. Our task
team envisages a standard system that allows interested
patients and participants to “pull” their genomic data
from clinical laboratories or research projects on
* Correspondence: adrian.thorogood@mcgill.ca; adrian.thorogood@ga4gh.org
1Centre of Genomics and Policy, Department of Human Genetics, McGill
University Faculty of Medicine, Montreal, Quebec H3A 0G1, Canada
Full list of author information is available at the end of the article
© The Author(s). 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Thorogood et al. Human Genomics  (2018) 12:7 
https://doi.org/10.1186/s40246-018-0139-5
request. Processes allowing individuals to access uninter-
preted data are different from policies or processes on
the return of individual findings. The latter are premised
on the information’s clinical relevance and/or actionabil-
ity. The right to access uninterpreted data does not
undermine the right not to know where it is provided on
request. Even so, there are concerns over the accuracy
and utility of uninterpreted data, and fears of misuse by
individuals or third party services may result in psycho-
logical harms or wasted health care resources [10].
Regardless, various research initiatives are opting to pro-
vide individual access, most notably the US “All of Us”
[11] and UK 100,000 Genomes [12] initiatives, and
participatory research projects such as the Personal
Genome Project [13]. Drawing on a review of current
practice and analysis of the legal right to access personal
health data, this paper supplies practical guidance for
clinical laboratories or research projects seeking to pro-
vide participants access to uninterpreted genomic data.
We recognize that it may not always be feasible or ap-
propriate to provide individual access, especially in some
(e.g., legacy) research contexts. We predict, however,
that individual access will become expected or required
as genomics becomes more clinically oriented and the
public begins to insist on participatory data governance.
Current practice
The projects providing or planning to provide individual
access to uninterpreted genomic data are listed in Table 1
(adapted from [14]). We were only able to identify one
such genomic sequencing project outside of the USA.
Data types and formats may differ depending on the
context, sequencing platform, analysis pipelines, and
evolution of common file formats. The examples of gen-
omic data formats currently provided to participants in-
clude reduced BAM, VCF, and FASTQ. The usefulness
of the data is enhanced where it is accompanied by rich,
standard metadata [15]. Genomic sequencing initiatives
may also provide individuals access to their associated
health data (phenotypic, clinical, environmental). The
choice of file format and the choice of when to provide
access should be considered from the perspective of
both the project and the individual.
Table 1 Projects providing individual access to genomic data
















Harvard PGP 2005- Research 352 WGS No Y Filtered
Variants w/
Lit Annot
No Yes (variants) No Nov 2017
BWH/Harvard
MedSeq
2011- Research 110 WGS Yes Monogenic,
Common,
PGx
Yes FASTQ Yes Nov 2017
Mount Sinai
HealthSeq
2012–2015 Research 40 WGS No Monogenic,
Common,
PGx
No BAM, VCF No paper
Mayo “10
scientists”





2014 Research 108 WGS No Monogenic,
Common,
PGx





2015– Research 160 WGS Yes Monogenic,
PGx





2015– Research 0 WES Yes Monogenic,
PGx
No BAM, VCF No paper





No BAM No Feb 2017
NIH All of Us 2017- Research 0 WGS ? ? ? ? ? Nov 2017
100,000
Genomes (UK)
2015- Research 44,633 WGS Yes Monogenic,
PGx
Yes Yesa Yes Jan 2018
Compiled as web site: Bobe, Jason. “sharing-genome-studies,” online: <http://blog.jasonbobe.net/sharing-genome-studies/>
aDoes not routinely provide access to BAM of VCF files, but participants are allowed to view the files on-site
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A legal right to access?
In many countries, individuals have a legal right to ac-
cess their personal data held by government bodies and
commercial entities [16–18]. A general right to access
personal data is included in the EU General Data Protec-
tion Regulation (GDPR) (art 15), which comes into force
in May 2018 [17]. This internationally recognized right
empowers individuals to ascertain what data these en-
tities have about them and how their personal data are
used. The right also enables individuals to ensure their
data are accurate, up to date, and used in a transparent,
fair, and lawful manner. Upon request, individuals must
be provided with a copy of their data in a reasonable
timeframe, in a useful format, and for a reasonable cost.
There is considerable uncertainty and jurisdictional vari-
ation over whether or not genetic data is legally consid-
ered inherently identifiable. Regardless, genomic data
will still fall under broad definitions of personal data
used in many jurisdictions (e.g., GDPR art 4(1)), as long
as it “relates to” an identifiable individual, which is in-
creasingly the case for linked genomic data in clinical,
commercial, and translational research contexts.
Similarly, patients have a legal right to access their
health record ([19], art. 19). This ensures transparency
in the physician-patient relationship and allows patients
to correct inaccurate information (which may be used by
third parties such as insurers) or transfer records when
changing physicians. Access to health data also em-
powers patients to take an active role in their health
care. Though raw laboratory data are not typically con-
sidered part of the health record, this is changing for
genomics. In the USA, recent legislative amendments
and interpretive guidance extend the right to access
under the US federal health privacy law to a broad range
of records that may be used to make decisions about in-
dividuals, including information generated as part of a
laboratory test [20]. For genetic sequencing, this might
include “the full gene variant information generated by
the test” [21]; for genomic sequencing, the raw sequence
data [22]. Genomic sequencing initiatives providing a
right to access should indicate this in the consent form,
along with the basic information on what is available
and how to request access. Consent forms should clearly
distinguish between access rights and other communica-
tion policies, such as the return of individual findings of
clinical relevance [13]. As we discuss below, more de-
tailed guidance can be provided to those individuals
requesting access at the point of implementation.
The right of access is generally subject to narrow ex-
ceptions: where it would reveal confidential information
(about other patients or health professionals), risk ser-
ious harm to the individual, or involve disproportionate
effort [23]. Providing an individual access to her own
genomic data would not generally breach professionals’
legal duties of confidentiality to third parties or present
serious risks to the individual. An important legal dis-
tinction for research contexts is that many countries
limit individual access to research data, usually to pro-
tect commercial interests and scientific validity [24]. It is
often unclear, however, if research exceptions in general
access to information provisions were meant to restrict
participants from accessing their own data [25]. Inter-
national and national research ethics guidelines are
largely silent about individual access to health data. This
is surprising, given that many incorporate other data
protection principles [26–28]. Some mention that partic-
ipants have the right to access their clinical data on de-
mand, unless temporary or permanent non-disclosure is
approved by a research ethics committee with reasons
([29], Table 2). Regardless, research exceptions are un-
likely to apply as sequencing moves to clinical or hybrid
clinical-research contexts. Researchers seeking to pro-
vide individuals with access to genomic data may also
have to contend with clinical services, clinical laboratory,
and/or medical product regulations. The US regulations,
for example, require any test results used for clinical
decision-making to be done in a certified laboratory
[30]. While these restrictions may block the return of
clinically relevant individual findings from research la-
boratories, it is not clear why they would also apply to
uninterpreted genomic data.
In conclusion, it is likely that clinical laboratories have,
or will soon have, a legal obligation to provide individ-
uals their raw genomic data upon request. While it is
less likely that a legal right applies in research contexts,
we propose that projects should still consider providing
a default right of participants to access their own
individual-level genomic data upon request. Any excep-
tions to access should be transparently stated, clearly
justified, and approved by a research ethics committee
or similar body. If access compromises the primary ob-
jective of the study, it could be withheld until the object-
ive is achieved. In both research and clinical contexts,
data stewards providing individual access should make
efforts to ensure data is of high quality and interoper-
able. Standard use agreements could accompany access
explaining that the data is provided “as is,” without im-
plied or express warranties (e.g., that the data is fit for a
particular purpose––namely clinical interpretation or
decision-making), and disclaiming liability for any harm
resulting from the individual’s use of the data.
Handling ethical and practical concerns
There are many good reasons for researchers to provide
access to individual-level uninterpreted data. Empirical
studies show that many people believe that their gen-
omic data belongs to them––that they have a right to
access, use, and distribute their data as they see fit
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[31]––even if this contradicts laws or consent forms
[32, 33]. Providing access may also build trust and
incentivize participation [34]. Moreover, patients are
often experts in their condition and may be more moti-
vated to determine the relevance of their health data
than researchers focused on discovery [35]. Access will
enable curious citizen scientists to explore the myriad
meanings of their DNA. Research may even thrive
when individuals themselves share data with patient-led
registries [36, 37], research projects, or public reposi-
tories like openSNP [38, 39] or Open Humans [39].
The usefulness of raw genomic data for the individual
will also increase with improvements in data quality
and interoperability, expansion of the knowledge base
of genotype-phenotype relationships, and the availabil-
ity of reliable third party services. The more data that is
held by individuals, the more portals to connect users
to research initiatives [40, 41]; interpretation services to
provide ancestry, genealogy, and health or wellness in-
formation; and tools to facilitate citizen science and
self-driven interpretation [42].
There are, however, concerns third party interpretation
services may provide uncertain, potentially inaccurate
information of little benefit and may lead to anxiety or
unnecessary medical follow-up [43]. To promote respon-
sible use, data stewards could provide individuals who
request access information about the limitations of data
quality, the limitations of self-directed or third party in-
terpretations, and the importance of secure storage and
responsible sharing. In particular, clarity is needed that
the data should not be used as a basis for clinical inter-
pretation or decision-making without seeking medical
advice and confirmatory testing in an accredited labora-
tory. User portals could facilitate download and commu-
nication, or even direct transfer/donation to trusted
storage platforms or research projects. Data stewards
should also ensure access processes are privacy protect-
ive and secure. They require basic authentication pro-
cesses (is this actually the participant?); tracking
processes (is this actually the participant’s genome?); and
a means of re-identifying a genome (how do I break the
code?). Researcher confidentiality may be breached if re-
questors are not properly authenticated, or if data from
the wrong genome is returned. Privacy concerns persist
after data has been accessed. Individuals may be ill-
prepared to keep their own data secure, and third party
services may not offer comparable privacy and security
protections [44]. Again, research projects could provide
individuals with tips on how to safeguard their data.
While researchers should do their best to encourage in-
dividuals to store and use their data carefully, the ultim-
ate responsibility to do so will rest with the individual.
There are also fears that access may divert resources
away from clinical or research activities. Moreover, indi-
viduals seeking professional interpretation of their data
could be a drain on primary care and genetic services
within the health system. This could waste public health
system resources and unfairly divert resources to the
most proactive, healthy, and educated individuals. Pro-
viding access should not, however, necessitate expensive
interpretation or counseling, as may be the case for the
Table 2 Summary of recommendations
Provide access to genomic data in standard formats
1) FASTQ: read-level data
2) BAM: Binary Alignment Map
3) gVCF: Genome Variant Call Format
4) FASTQ: assembled diplotype genome
(Ability to reconstruct genomes: FASTQ ~ = BAM > gVCF > FASTQ)
Provide access upon request unless withholding access is justified (by
an Access Office or Research Ethics Committee)
1) Breaching confidentiality of a third party (could consent from
the third party be obtained?)
2) Imminent and serious harm to the mental or physical health
of the individual (could the harm be mitigated?)
3) Access compromises a primary objective of a research study
(could access instead be provided at the end of the study?)
4) Expense compromises the feasibility of a research study
(could participants be asked to cover the costs?)
Establish appropriate data tracking and security processes
1) Authentication service (e.g., Experian) or in-person account creation
2) Best practices for data security (encryption, user access controls,
transfer protocols)
Describe the right to access in the consent form
1) Distinguish from the plan for return of individual findings of
clinical relevance
Provide detailed information at the point of access
1) Participant’s right to access uninterpreted data
2) Description of access process
3) Description of risks posed by research-grade data
4) Description of benefits provided by uninterpreted genetic data
5) Description of available genetic counseling services
6) Description of how data will be accessed, stored, and transferred
No warranty and disclaimers
1) Clear articulation that data may not meet clinical standards,
and should not be used as a basis for clinical interpretation or
decision-making without medical advice and confirmatory testing
in an accredited laboratory
2) Clear disclaimers that research sponsors do not offer a warranty
of the data accuracy and are not liable for harm caused from using
the data
3) Research sponsors should still strive to generate the highest
quality data
Funders
1) Incentivize projects to provide participants access
2) Support costs of participant access
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return of individual results. Costs would be limited to
basic tracking, authentication, and communication pro-
cesses––already common in many laboratory contexts
and clinical practices––and download costs.
Currently, many researchers feel they should provide ac-
cess to individual-level data to patients and participants,
but do not have the appropriate resources to do so. To ad-
dress this problem, research funding bodies could help by
providing resources, infrastructure, and incentives. Instead
of each project establishing its own system, common data
management platforms could be developed to enable indi-
vidual access (such as those already offered to researchers
by direct-to-consumer companies) [45]. Data sharing re-
positories enabling broad research community access
could be modified to enable individual access. Individual
access endorsements or badges could recognize laboratory
or researcher efforts to share data with interested partici-
pants and patients.
Conclusion
We provide a summary of recommendations for sequen-
cing initiatives providing individual access to uninter-
preted genomic data in Table 2. More data and experience
is needed to definitively refute paternalist concerns about
individuals managing their own genomic data. This will
only happen if researchers do what they do best: experi-
ment in a responsible manner to understand how to most
appropriately support and enable individual access to gen-
omic data. Here, the variable to tweak is not the data ana-
lysis, but the participant communication pipeline. The
experiment is off to a promising start.
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